371 related articles for article (PubMed ID: 18682881)
1. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
[TBL] [Abstract][Full Text] [Related]
2. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
3. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
[TBL] [Abstract][Full Text] [Related]
5. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of
Toriihara A; Ohtake M; Tateishi K; Hino-Shishikura A; Yoneyama T; Kitazume Y; Inoue T; Kawahara N; Tateishi U
Ann Nucl Med; 2018 May; 32(4):264-271. PubMed ID: 29453680
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
9. PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.
Zhang T; Das SK; Fels DR; Hansen KS; Wong TZ; Dewhirst MW; Vlahovic G
AJR Am J Roentgenol; 2013 Nov; 201(5):W698-706. PubMed ID: 24147499
[TBL] [Abstract][Full Text] [Related]
10. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
11. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
[TBL] [Abstract][Full Text] [Related]
13. Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Lutsyk M; Awawda M; Gourevich K; Ben Yosef R
Am J Clin Oncol; 2021 Sep; 44(9):482-486. PubMed ID: 34269693
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
15. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
Grassi I; Nanni C; Cicoria G; Blasi C; Bunkheila F; Lopci E; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Jan; 39(1):e59-63. PubMed ID: 24097008
[TBL] [Abstract][Full Text] [Related]
17. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
[TBL] [Abstract][Full Text] [Related]
18. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
Nie X; Randolph GJ; Elvington A; Bandara N; Zheleznyak A; Gropler RJ; Woodard PK; Lapi SE
Nucl Med Biol; 2016 Sep; 43(9):534-542. PubMed ID: 27372286
[TBL] [Abstract][Full Text] [Related]
19. Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort.
Tsuchiya J; Yoneyama T; Ohtake M; Tateishi K; Bae H; Kishino M; Tateishi U
Nucl Med Commun; 2020 Jun; 41(6):567-574. PubMed ID: 32371672
[TBL] [Abstract][Full Text] [Related]
20. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
